The Top Line Navigating Trump’s tariffs for pharma
6 snips
Apr 18, 2025 The discussion dives into the impact of recent tariffs on the pharmaceutical and life sciences industries. Experts uncover the potential disruptions in supply chains and manufacturing strategies due to escalating trade pressures. Highlighted are the financial challenges and the significant uncertainties regarding sector-specific duties. Innovative approaches and the role of artificial intelligence in enhancing operational efficiency and drug development are also explored, emphasizing the need for strategic planning amidst these shifting landscapes.
AI Snips
Chapters
Transcript
Episode notes
Tariff Impact Goes Beyond Finished Drugs
- Finished pharmaceutical products may avoid tariffs, but APIs and supply chain parts are often included.
- This complexity means tariffs could impact pharma production costs broadly.
Manufacturing Moves Amid Tariffs
- Some pharma companies already started shifting manufacturing out of China to Singapore and from Mexico to the U.S. due to trade and talent issues.
- These shifts have ramped up more recently because of tariffs and geopolitical pressures.
CDMOs Also Vulnerable to Tariffs
- CDMOs and contractors face tariff exposure because they must purchase materials and equipment.
- Complex supply chains for innovative therapies like cell and gene face amplified challenges under tariffs.